Disc Medicine, Inc. (NASDAQ:IRON) Shares Acquired by GAMMA Investing LLC

GAMMA Investing LLC increased its stake in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 5,092.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,410 shares of the company's stock after buying an additional 12,171 shares during the period. GAMMA Investing LLC's holdings in Disc Medicine were worth $616,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Sterling Capital Management LLC increased its stake in shares of Disc Medicine by 798.4% in the fourth quarter. Sterling Capital Management LLC now owns 566 shares of the company's stock worth $36,000 after buying an additional 503 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in Disc Medicine during the fourth quarter valued at $40,000. Tower Research Capital LLC TRC increased its stake in Disc Medicine by 47.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 825 shares of the company's stock valued at $52,000 after purchasing an additional 266 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in Disc Medicine during the fourth quarter valued at $235,000. Finally, Fiduciary Trust Co bought a new stake in Disc Medicine during the fourth quarter valued at $257,000. Institutional investors own 83.70% of the company's stock.

Analyst Ratings Changes

IRON has been the subject of several recent research reports. Scotiabank boosted their target price on shares of Disc Medicine from $73.00 to $75.00 and gave the company a "sector outperform" rating in a research note on Monday, March 3rd. Wedbush reiterated an "outperform" rating and set a $90.00 target price on shares of Disc Medicine in a research note on Monday, June 16th. Morgan Stanley reiterated an "overweight" rating and set a $85.00 target price on shares of Disc Medicine in a research note on Friday, March 7th. Raymond James Financial initiated coverage on shares of Disc Medicine in a research note on Wednesday, June 11th. They set a "strong-buy" rating and a $89.00 target price for the company. Finally, BMO Capital Markets boosted their target price on shares of Disc Medicine from $112.00 to $120.00 and gave the company an "outperform" rating in a research note on Monday, May 12th. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $96.70.

Insider Transactions at Disc Medicine

In related news, Director Mona Ashiya sold 5,738 shares of the company's stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $54.11, for a total value of $310,483.18. Following the completion of the sale, the director now owns 186,541 shares of the company's stock, valued at $10,093,733.51. This represents a 2.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Jean M. Franchi sold 2,000 shares of the company's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $52.26, for a total transaction of $104,520.00. Following the completion of the sale, the chief financial officer now directly owns 67,530 shares of the company's stock, valued at $3,529,117.80. The trade was a 2.88% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 19,511 shares of company stock worth $1,004,277. Insiders own 4.24% of the company's stock.

Disc Medicine Stock Performance

Shares of Disc Medicine stock traded up $1.52 during trading on Friday, hitting $51.61. 413,971 shares of the stock were exchanged, compared to its average volume of 341,858. The stock's fifty day moving average is $47.22 and its 200 day moving average is $52.73. The stock has a market cap of $1.79 billion, a PE ratio of -13.17 and a beta of 0.73. The company has a debt-to-equity ratio of 0.04, a quick ratio of 37.65 and a current ratio of 37.65. Disc Medicine, Inc. has a 12 month low of $30.82 and a 12 month high of $68.73.

Disc Medicine (NASDAQ:IRON - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.99) by ($0.03). As a group, sell-side analysts anticipate that Disc Medicine, Inc. will post -4.07 EPS for the current year.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.